Opioid analgesics/voriconazole
- PDF / 169,444 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 12 Downloads / 184 Views
1 S
Visual hallucinations and vision symptoms: 2 case reports In a retrospective, multi-centre study performed between April 2015 and March 2018 in Japan, involving 401 patients, who received antifungal therapy with voriconazole, two patients [ages and sexes not stated] were described, who developed visual hallucinations or unspecified vision symptoms (1 patient each) secondary to voriconazole. Of these, the patient who developed unspecified vision symptoms, additionally received an unspecified opioid analgesic, which also contributed to the development of vision symptoms [routes, doses and durations of treatments to reactions onsets not stated]. Both patients started receiving antifungal therapy with voriconazole BID. One of these patients was also receiving an unspecified opioid analgesic. However, the patients subsequently developed visual hallucinations secondary to voriconazole, or unspecified vision symptoms secondary to voriconazole and the opioid analgesic. The dose of voriconazole was reduced for the patient, who developed visual hallucinations, resulting in subsequent improvement. The other patient, who received voriconazole and an opioid analgesic, did not exhibit improvement in visual symptoms. Hamada Y, et al. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual 803507377 symptoms: A multicentre study conducted in Japan. Mycoses 63: 779-786, No. 8, Aug 2020. Available from: URL: http://doi.org/10.1111/myc.13129
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
